Pain Control after Laparoscopic Inguinal Hernia Repair: Comparing TAP Block and Local Instillation

A Randomized Controlled Trial Comparing Transversus Abdominis Plane (TAP) Block with Preperitoneal Instillation of 0.5% Bupivacaine for Postoperative Pain Control in Laparoscopic Totally Extraperitoneal (TEP) Inguinal Hernia Repair

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20251030001

Enrollment

Registered

2025-10-30

Start date

2025-10-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inguinal hernia Postoperative pain Inguinal Hernia Herniorrhaphy Laparoscopy Pain, Postoperative Analgesia Bupivacaine Transversus Abdominis Plane Block Anesthesia, Local

Interventions

At the end of surgery, before desufflation, 20 mL of 0.33% bupivacaine will be instilled into the preperitoneal space. In addition, standardized port site infiltration will be performed with 5 mL at t

Experimental Drug,Experimental Drug

Preperitoneal instillation of bupivacaine,Transversus Abdominis Plane (TAP) block with bupivacaine

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age 18 years or older 2.Diagnosed with primary unilateral inguinal hernia 3.Scheduled for elective laparoscopic totally extraperitoneal (TEP) hernia repair 4.ASA physical status I to III 5.Ability to provide written informed consent

Exclusion criteria

Exclusion criteria: 1.Recurrent or bilateral inguinal hernia 2.Incarcerated or strangulated inguinal hernia 3Giant inguinal hernia greater than half thigh length 4.Contraindication to local anesthetics (e.g. allergy to bupivacaine) 5.Coagulopathy or anticoagulant therapy 6.Severe cardiopulmonary disease contraindicating laparoscopy 7.Previous lower abdominal surgery affecting preperitoneal space 8.Chronic opioid use or substance abuse 9.Body weight less than 40 kg 10.Inability to communicate or use VAS/NRS reliably

Design outcomes

Primary

Measure	Time frame
VAS pain with movement at 6 hours 6 hours post operation Visual Analog Scale 0 to 10 cm during standardized cough movement	—

Secondary

Measure	Time frame
VAS pain at rest at 6 hours 6 hours post operation Visual Analog Scale 0 to 10 cm,VAS pain with movement at 2, 12, 24 hours 2 hours, 12 hours, 24 hours Visual Analog Scale 0 to 10 cm during standardized cough movement,Time to first rescue analgesia within 24 hours Hours from PACU arrival to first request with NRS pain score greater than or equal to 4,Total opioid consumption 24 hours post operation Oral morphine milligram equivalents 0 to 24 hours,Recovery parameters In hospital until discharge Time to first sit stand walk, first void, Modified PADSS score, hospital stay length,Postoperative complications 24 hours and 30 days Incidence of PONV urinary retention hematoma seroma SSI paresthesia LAST,Patient satisfaction with analgesia 24 hours post operation Numeric Rating Scale 0 to 10,Return to normal activities or work Day 14 and Day 30 Days to return and proportion resumed activity	—

Measure

Time frame

VAS pain at rest at 6 hours 6 hours post operation Visual Analog Scale 0 to 10 cm,VAS pain with movement at 2, 12, 24 hours 2 hours, 12 hours, 24 hours Visual Analog Scale 0 to 10 cm during standardized cough movement,Time to first rescue analgesia within 24 hours Hours from PACU arrival to first request with NRS pain score greater than or equal to 4,Total opioid consumption 24 hours post operation Oral morphine milligram equivalents 0 to 24 hours,Recovery parameters In hospital until discharge Time to first sit stand walk, first void, Modified PADSS score, hospital stay length,Postoperative complications 24 hours and 30 days Incidence of PONV urinary retention hematoma seroma SSI paresthesia LAST,Patient satisfaction with analgesia 24 hours post operation Numeric Rating Scale 0 to 10,Return to normal activities or work Day 14 and Day 30 Days to return and proportion resumed activity

—

Countries

Thailand

Contacts

Public ContactThita Intralawan

Ratchaburi Hospital

tintralawan@gmail.com66879892898

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026